CEMATRIX Announces $6.2 Million Increase in Contracts
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (OTCQB: CTXXF) (“CEMATRIX” or the “Company“) a North […]
Safe & Green Holdings CEO Provides Letter to Shareholders
Safe & Green Holdings’ Modular Manufacturing Facility MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: […]
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical […]
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that […]
NewtekOne, Inc. Announces Record Loan Closings for the Fourth Quarter and Full Year 2023
BOCA RATON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT), announced today that […]
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with […]
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract […]
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for […]
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases ABATE Phase 1b/2 AD […]
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company […]
